First DOC1021 patients treated in Phase 1/2 refractory melanoma trial
DOC1021 enters a Phase 1/2 refractory melanoma trial testing personalised dendritic cell therapy without lymphodepletion or high-dose IL-2
Pharma & Biotech
Medical Devices & Diagnostics
Why Natera’s Diakonos Oncology collaboration matters for ctDNA-guided cancer drug development
Natera’s Signatera will track molecular response in a refractory melanoma trial. Find out why ctDNA is becoming central to oncology R&D.
Pharma & Biotech
Can Diakonos Oncology’s DOC1021 reawaken immune response in refractory melanoma?
Diakonos Oncology Corporation has received over $7 million from the Cancer Prevention and Research Institute of Texas to initiate a Phase 1/2 clinical trial of its double-loaded dendritic cell therapy, DOC1021, in patients with refractory melanoma. The grant places the investigational therapy into its third solid tumor indication and signals rising institutional interest in immune-based